Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

C-terminal binding protein 2 is a novel tumor suppressor targeting the MYC-IRF4 axis in multiple myeloma

8 Mar 2024

Abstract excerpt

ABSTRACT: Multiple myeloma (MM) cells are addicted to MYC and its direct transactivation targets IRF4 for proliferation and survival. MYC and IRF4 are still considered "undruggable," as most small-molecule inhibitors suffer from low potency, suboptimal pharmacokinetic properties, and undesirable off-target effects. Indirect inhibition of MYC/IRF4 emerges as a therapeutic vulnerability in MM. Here, we uncovered an...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Multiple Myeloma Research and Treatments
Share to Protein Degradation and Inhibitors
Share to Ubiquitin and proteasome pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38457926
DOI: 10.1182/bloodadvances.2023010218

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

C-terminal binding protein 2 is a novel tumor suppressor targeting the MYC-IRF4 axis in multiple myelomaPMID 38457926Read ↗

Bromodomain inhibition of the transcriptional coactivators CBP/EP300 as a therapeutic strategy to target the IRF4 network in multiple myelomaSemantic proximity Read ↗

IRF4 in multiple myeloma—Biology, disease and therapeutic targetSemantic proximity Read ↗

REIIBP promotes TLR7-BTK-IL6 pro-inflammatory response through histone H3 lysine methylation in t(4;14) myelomagenesisSemantic proximity Read ↗

ETV4-Dependent Transcriptional Plasticity Maintains MYC Expression and Results in IMiD Resistance in Multiple MyelomaSemantic proximity Read ↗

Epigenetic dysregulation of eukaryotic initiation factor 3 subunit E (eIF3E) by lysine methyltransferase REIIBP confers a pro-inflammatory phenotype in t(4;14) myeloma.Semantic proximity Read ↗

EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functionsSemantic proximity Read ↗

Research Progress of Protein Arginine Methyltransferases (PRMTs) in Multiple Myeloma: From Molecular Mechanisms to Targeted TherapySemantic proximity Read ↗

The innate sensor ZBP1-IRF3 axis regulates cell proliferation in multiple myelomaSemantic proximity Read ↗

c‐FOS is an integral component of the IKZF1 transactivator complex and mediates lenalidomide resistance in multiple myelomaSemantic proximity Read ↗

Revised International Staging System (R-ISS) stage-dependent analysis uncovers oncogenes and potential immunotherapeutic targets in multiple myelomaSemantic proximity Read ↗

Biological Hallmarks and Emerging Strategies to Target STAT3 Signaling in Multiple MyelomaSemantic proximity Read ↗

Loss of BCL7A permits IRF4 transcriptional activity and cellular growth in multiple myelomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.